Last $0.63 USD
Change Today +0.01 / 1.61%
Volume 211.5K
CVM On Other Exchanges
As of 8:04 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

cel-sci corp (CVM) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/21/14 - $1.90
52 Week Low
12/10/14 - $0.54
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CEL-SCI CORP (CVM)

Related News

No related news articles were found.

cel-sci corp (CVM) Related Businessweek News

No Related Businessweek News Found

cel-sci corp (CVM) Details

CEL-SCI Corporation engages in the research and development of drugs and vaccines. The company’s lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. Multikine is also being used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System (LEAPS), a patented T-cell modulation process, stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune, allergies, transplantation rejection, and cancer. The company, through its LEAPS technology, provides peptide treatment for H1N1 hospitalized patients; and CEL-2000, a rheumatoid arthritis vaccine. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.

cel-sci corp (CVM) Top Compensated Officers

Chief Executive Officer, Principal Financial ...
Total Annual Compensation: $584.6K
Founder, Chairman and President
Total Annual Compensation: $393.3K
Senior Vice President of Operations and Corpo...
Total Annual Compensation: $247.9K
Senior Vice President of Research - Cellular ...
Total Annual Compensation: $213.2K
Senior Vice President of Regulatory Affairs
Total Annual Compensation: $197.4K
Compensation as of Fiscal Year 2014.

cel-sci corp (CVM) Key Developments

CEL-SCI Corporation Reports Consolidated Earnings Results for the Full Year Ended September 30, 2014

CEL-SCI Corporation reported consolidated earnings results for the full year ended September 30, 2014. For the full year, the company reported an operating loss of $27.57 million versus an operating loss of $19.87 million in fiscal year 2013. The rise in operating loss was attributable to an increase in research and development expenses to $17.0 million in fiscal year 2014 compared to $12.68 million in fiscal year 2013. The company’s net loss available to common shareholders was $28.48 million, or $0.49 per diluted share, versus a loss of $9.23 million, or $0.66 per diluted share for the fiscal year 2013. The change in net loss available to common shareholders in fiscal year 2014 was primarily due to the gain on derivative instruments of $0.25 million for fiscal year 2014 versus a gain on derivative instruments of $10.75 million for fiscal year 2013 and an increase in total operating expenses of $27.84 million for fiscal year 2014 versus $20.03 million for fiscal year 2013. Grant income and other was $264,033 compared to $159,583 a year ago.

CEL-SCI Corporation announced delayed annual 10-K filing

On 12/12/2014, CEL-SCI Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.

CEL-SCI Enrolls 22 Patients During October in its Phase III Immunotherapy Head and Neck Cancer Trial

CEL-SCI Corporation announced that during the month of October the Company enrolled 22 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine (Leukocyte Interleukin, Injection). This brings the total number patients enrolled in the world's large Phase III trial for head and neck cancer to almost 300. A total of 880 patients are expected to be enrolled, through 100 clinical centers in over 20 countries. The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care (SOC) vs. subjects who are treated with SOC only. CEL-SCI's Multikine investigational immunotherapy is intended to create an anti-tumor immune response to reduce local/regional tumor recurrence and thereby increase the survival rate of these patients.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CVM:US $0.63 USD +0.01

CVM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CVM.
View Industry Companies

Industry Analysis


Industry Average

Valuation CVM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 157.9x
Price/Book 4.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 181.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CEL-SCI CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at